Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05870917
Other study ID # CAC-PPCL-001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 25, 2023
Est. completion date April 2027

Study information

Verified date February 2024
Source Institute of Hematology & Blood Diseases Hospital, China
Contact Gang An, PhD&MD
Phone 86-022-23909171
Email angang@ihcams.ac.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.


Description:

The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) in combination with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia. Patients receive 3 cycles of induction therapy with VRD-based regimen followed by the first infusion of CAR-T cells. Patients then received 3 cycles of VR-based consolidation therapy, followed by ASCT and the second infusion of CAR-T cells. And R or R maintenance starts on day 100 after ASCT.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date April 2027
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. 2. Age = 18 years and = 65 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. 4. Life expectancy at least 3 months 5. Definitive diagnosis of pPCL: meet the diagnosis criteria of multiple myeloma (refer to the Chinese guidelines for the diagnosis and management of multiple myeloma (revised 2022) criteria) and meeting any of the following: 1. the proportion of tumor plasma cells in peripheral blood leukocytes = 5%; 2. absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10^9/L. 6. Patients have not received previous anti-myeloma related therapy. 7. Measurable disease, as defined by at lease one of the following: 1. Serum monoclonal paraprotein (M-protein) level =5g/L. 2. urine M-protein level =200 mg/24 hours. 3. If the serum and urine M-protein are unmeasurable, abnormal serum free light chain (FLC) ratio and affected FLC =10 mg/dL. 8. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination. 9. Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : ANC = 1.0 x 10^9/L, PLT = 50 x 10^9/L. 10. All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: 1. Total bilirubin<1.5 x upper limit of normal (ULN); 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST); 3. Creatinine clearance = 50mL/min (calculated using Cockroft-Gault formula). 11. Patients must be able to take prophylactic anticoagulant therapy as recommended by the study. 12. The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter. 13. Willing and able to complete the study procedures and follow-up examinations. Exclusion Criteria: 1. Secondary plasma cell leukemia. 2. With central nervous system (CNS) involvement. 3. Ineligible for autologous stem cell transplantation, such as severe cardiopulmonary disorders. 4. Known intolerant, allergic, or resistant to glucocorticoids, bortezomib, lenalidomide, Venetoclax, Selinexor and BCMA-CART cellular products. 5. Patients had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period. 6. Patients with unstable or active cardiovascular system disease, meeting any of the following: 1. Unstable angina pectoris, symptomatic myocardial ischaemia, myocardial infarction or coronary artery reconstruction within 180 days prior to the first dose. 2. Uncontrolled hypertension (>140/90 mmHg with blood pressure fluctuations of more than 180/100 mmHg over a 6-month period). 3. Uncontrolled and clinically significant conduction abnormalities (e.g. patients with ventricular arrhythmias controlled by antiarrhythmic medication), not excluding patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior bundle branch block/right bundle branch block (LAFB/RBBB)). 4. Congestive heart failure (CHF) classification = grade 3 as defined by the New York Heart Association (NYHA). 5. Left ventricular ejection fraction (LVEF) <50% on echocardiography. 6. History of stroke or intracranial haemorrhage within 12 months prior to screening. 7. Presence of a serious thrombotic event prior to treatment. 7. Known positive serology for HIV or HIV seropositivity. 8. Active hepatitis B or C infection. Screening requires serologic testing for hepatitis. If hepatitis B surface antigen and hepatitis B core antibody were positive, a negative DNA polymerase chain reaction (PCR) result was needed before enrollment (after anti-hepatitis B therapy, a negative DNA polymerase PCR result was confirmed before enrollment). If the hepatitis C antibody was positive, the RNA PCR test should be negative prior to enrollment. 9. Ongoing active infection. 10. Prior history of malignancies, unless free of the disease for = 5 years. 11. Pregnant or breast feeding females. 12. Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication. 13. According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent. 14. Necessary medication or supportive therapy is contraindicated with study treatment. 15. Any other medical condition or comorbidity that might interfere with subject's participation. 16. Patients undergoing other experimental therapies. 17. Patients are not willing to or cannot comply with study scheme.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
anti-BCMA CAR-T
Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20% x 10^6 anti-BCMA CAR+T cells/kg respectively

Locations

Country Name City State
China Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Institute of Hematology & Blood Diseases Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The CART cell duration in vivo The copies of BCMA-CART DNA in peripheral blood with qPCR method 1 year
Primary Safety and Tolerability The incidence of treatment-emergent adverse events (TEAEs) 2 year
Primary Overall response rate (ORR) ORR(including sCR / CR / VGPR / PR, based on IMWG criteria) after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion
Primary Progression free survival (PFS) Is defined as time from first induction date to first documentation of PD, or death due to any cause, whichever occurs first. 1 year
Secondary Complete response rate (CRR) CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response according to IMWG criteria after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion
Secondary Overall survival (OS) Is defined as time from first induction date to time of death due to any cause 1 year
Secondary MRD-negative Rate MRD negative by flow cytometry after induction therapy, 1 month after the first CAR-T cell transfusion, the consolidation therapy ends, 6 months after the second CAR-T cell transfusion
Secondary Duration of Remission (DOR) Duration from the first evaluation of at least partial remission (PR) to the onset of disease progression or death due to disease progression (whichever occurs first) 2 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01435720 - Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Phase 1/Phase 2
Recruiting NCT01328236 - Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Phase 2
Completed NCT02506959 - Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Phase 2
Withdrawn NCT03591744 - Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia Phase 1
Not yet recruiting NCT05054478 - Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation Phase 2
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Recruiting NCT05805605 - Allo HSCT Using RIC and PTCy for Hematological Diseases Phase 2
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Recruiting NCT05759793 - A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia Phase 1
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Completed NCT01008462 - Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Phase 2
Recruiting NCT05219721 - A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia Phase 1
Completed NCT00307086 - Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Phase 2
Active, not recruiting NCT01729091 - Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 2
Recruiting NCT05823571 - Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Phase 1
Recruiting NCT06045091 - To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL Early Phase 1
Recruiting NCT05556928 - Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Completed NCT02504359 - Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Phase 1
Recruiting NCT05979363 - A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia Phase 2
Recruiting NCT05283993 - A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH